ABSTRACT
Mutations in the BRCA1 and BRCA2 genes increase the risk for various cancers including breast, ovarian, prostate, pancreas and melanoma. Identifying BRCA1/2 mutation carriers enables risk assessment, surveillance, early detection and risk reduction. In certain Israeli sub-populations recurring and founder mutations have been identified and for these, testing for founder mutations is simple, efficient and cost-effective. Founder mutations in the Jewish Ethiopian population have not been described. We report here the identification of a recurring BRCA2 mutation in the Ethiopian Jewish population; c.5159C>A; p.Ser1720Ter, which has only been described once before in this population. In addition, in another family of the same origin we found the BRCA2 c.7579delG; p.Val2527Ter mutation that has been previously described in two different Jewish Ethiopian families. In Israel genetic testing is performed in a sequential stepwise manner, first testing a panel of predominant mutations and if negative further testing by gene sequencing is offered. Recently it has been decided to expand the founder mutation panel to include mutations which have been found in two or more separate families. This new panel will include the BRCA2 c.7579delG; p.Val2527Ter mutation, and we recommend that the BRCA2 c.5159C>A; p.Ser1720Ter mutation should also be added to the new predominant mutation panel.
Subject(s)
Genes, BRCA2 , Jews , BRCA2 Protein/genetics , Ethiopia , Genetic Testing , Humans , Jews/genetics , Male , MutationABSTRACT
PURPOSE: While the spectrum of germline mutations in BRCA1/2 genes in the Israeli Jewish population has been extensively studied, there is a paucity of data pertaining to Israeli Arab high-risk cases. METHODS: Consecutive Israeli Arab breast and/or ovarian cancer patients were recruited using an ethically approved protocol from January 2012 to February 2019. All ovarian cancer cases were referred for BRCA genotyping. Breast cancer patients were offered BRCA sequencing and deletion/duplication analysis after genetic counseling, if the calculated risk for carrying a BRCA mutation by risk prediction algorithms was ≥10%. RESULTS: Overall, 188 patients participated; 150 breast cancer cases (median age at diagnosis: 40 years, range 22-67) and 38 had ovarian cancer (median age at diagnosis: 52.5 years, range 26-79). Of genotyped cases, 18 (10%) carried one of 12 pathogenic or likely-pathogenic variants, 12 in BRCA1, 6 in BRCA2. Only one was a rearrangement. Three variants recurred in more than one case; one was detected in five seemingly unrelated families. The detection rate for all breast cancer cases was 4%, 5% in bilateral breast cancer cases and 3% if breast cancer was diagnosed < 40 years. Of patients with ovarian cancer, 12/38 (32%) were carriers; the detection rate reached 75% (3/4) among patients diagnosed with both breast and ovarian cancer. CONCLUSIONS: The overall yield of comprehensive BRCA1/2 testing in high-risk Israeli Arab individuals is low in breast cancer patients, and much higher in ovarian cancer patients. These results may guide optimal cancer susceptibility testing strategy in the Arab-Israeli population.
Subject(s)
Arabs/genetics , BRCA1 Protein/genetics , BRCA2 Protein/genetics , Breast Neoplasms/diagnosis , Genotyping Techniques/methods , Ovarian Neoplasms/diagnosis , Adult , Aged , Breast Neoplasms/genetics , Early Detection of Cancer , Female , Genetic Counseling , Genetic Predisposition to Disease , Genetic Variation , Germ-Line Mutation , Humans , Israel/ethnology , Middle Aged , Ovarian Neoplasms/genetics , Young AdultABSTRACT
OBJECTIVES: The purpose of this study was to characterize the population referred to the Maritime Medical Genetics Service (MMGS) because of increased risk of breast and/or ovarian cancer, and to evaluate the MMGS referral criteria for this population. METHODS: We reviewed a retrospective cohort of patients at increased risk of breast and/or ovarian cancer (n = 574) with appointments between January 2001 and May 2007 at the MMGS. Data analysis was performed using descriptive statistics in Filemaker Pro 8.5v1 and Microsoft Excel. RESULTS: Among 574 patients, 253 (44%) had test results available at the time of data collection, and 65 (25.7%) had BRCA mutations (44 BRCA1 and 21 BRCA2). Positive test results for each referral criterion ranged from 0% to 100%. CONCLUSION: Use of referral criteria at the MMGS yielded higher rates of positive test results than previously thought. It may be beneficial to expand testing criteria to ensure that everyone who may carry a mutation is offered testing.
Subject(s)
Breast Neoplasms/genetics , Genetic Testing , Ovarian Neoplasms/genetics , Adolescent , Adult , Aged , Breast Neoplasms/epidemiology , Canada , Cohort Studies , Female , Genes, BRCA1 , Genes, BRCA2 , Humans , Male , Middle Aged , Mutation , Ovarian Neoplasms/epidemiology , Referral and Consultation , Retrospective StudiesABSTRACT
The medical significance of N-glycosylation is underlined by a group of inherited human disorders called Congenital Disorders of Glycosylation (CDG). One key step in the biosynthesis of the Glc(3)Man(9)GlcNAc(2)-PP-dolichol precursor, essential for N-glycosylation, is the translocation of Man(5)GlcNAc(2)-PP-dolichol across the endoplasmic reticulum membrane. This step is facilitated by the RFT1 protein. Recently, the first RFT1-deficient CDG (RFT1-CDG) patient was identified and presented a severe N-glycosylation disorder. In the present study, we describe three novel CDG patients with an RFT1 deficiency. The first patient was homozygous for the earlier reported RFT1 missense mutation (c.199C>T; p.R67C), whereas the two other patients were homozygous for the missense mutation c.454A>G (p.K152E) and c.892G>A (p.E298 K), respectively. The pathogenic character of the novel mutations was illustrated by the accumulation of Man(5)GlcNAc(2)-PP-dolichol and by reduced recombinant DNase 1 secretion. Both the glycosylation pattern and recombinant DNase 1 secretion could be normalized by expression of normal RFT1 cDNA in the patients' fibroblasts. The clinical phenotype of these patients comprised typical CDG symptoms in addition to sensorineural deafness, rarely reported in CDG patients. The identification of additional RFT1-deficient patients allowed to delineate the main clinical picture of RFT1-CDG and confirmed the crucial role of RFT1 in Man(5)GlcNAc(2)-PP-dolichol translocation.
Subject(s)
Carbohydrate Metabolism, Inborn Errors/genetics , Membrane Glycoproteins/genetics , Cells, Cultured , Chromatography, High Pressure Liquid , Female , Genetic Complementation Test , Humans , Male , PhenotypeABSTRACT
We report a child with polycythemia vera (PV). This patient demonstrates the acquired somatic JAK2 V617F mutation and also has neurofibromatosis type I (NF1). NF1, while not previously associated with PV, is associated with another childhood MPD, juvenile myelomonocytic leukemia (JMML). Thus we examined a number of genetic abnormalities identified in JMML patients, but found no association in this case. Neurofibromin sequencing failed to identify a causative mutation. An unknown genetic abnormality resulting in NF1 may have predisposed this young child to acquiring the common JAK2 mutation.
Subject(s)
Janus Kinase 2/genetics , Neurofibromatosis 1/complications , Polycythemia Vera/complications , Polycythemia Vera/genetics , DNA Mutational Analysis , Female , Humans , Infant , Mutation , Neurofibromatosis 1/physiopathology , Polycythemia Vera/physiopathology , Polymerase Chain ReactionABSTRACT
BACKGROUND: Fanconi anemia complementation group C and Bloom syndrome, rare autosomal recessive disorders marked by chromosome instability, are especially prevalent in the Ashkenazi* Jewish community. A single predominant mutation for each has been reported in Ahshkenazi Jews: c.711+4A-->T (IVS4 +4 A-->T) in FACC and BLM(Ash) in Bloom syndrome. Individuals affected by either of these syndromes are characterized by susceptibility for developing malignancies, and we questioned whether heterozygote carriers have a similarly increased risk. OBJECTIVES: To estimate the cancer rate among FACC and BLM(Ash) carriers and their families over three previous generations in unselected Ashkenazi Jewish individuals. METHODS: We studied 42 FACC carriers, 28 BLM(Ash) carriers and 43 controls. The control subjects were Ashkenazi Jews participating in our prenatal genetic screening program who tested negative for FACC and BLM(Ash). All subjects filled out a questionnaire regarding their own and a three-generation family history of cancer. The prevalence rates of cancer among relatives of FACC, BLM(Ash) and controls were computed and compared using the chi-square test. RESULTS: In 463 relatives of FACC carriers, 45 malignancies were reported (9.7%) including 10 breast (2.2%) and 13 colon cancers (2.8%). Among 326 relatives of BLM(Ash) carriers there were 30 malignancies (9.2%) including 7 breast (2.1%) and 4 colon cancers (1.2%). Controls consisted of 503 family members with 63 reported malignancies (12.5%) including 11 breast (2.2%) and 11 colon cancers (2.2%). CONCLUSIONS: We found no significantly increased prevalence of malignancies among carriers in at least three generations compared to the controls.
Subject(s)
Bloom Syndrome/ethnology , Bloom Syndrome/epidemiology , Breast Neoplasms/ethnology , Breast Neoplasms/epidemiology , Colorectal Neoplasms/ethnology , Colorectal Neoplasms/epidemiology , Fanconi Anemia/ethnology , Fanconi Anemia/epidemiology , Heterozygote , Jews/genetics , Mutation/genetics , Adult , Bloom Syndrome/genetics , Breast Neoplasms/genetics , Case-Control Studies , Colorectal Neoplasms/genetics , Fanconi Anemia/genetics , Female , Humans , Israel/epidemiology , Male , Prevalence , Risk AssessmentABSTRACT
BACKGROUND: von Hippel-Lindau (VHL) disease is a hereditary tumor syndrome in which affected individuals may develop CNS and retinal hemangioblastomas, pheochromocytomas, renal cell carcinoma, and cysts of various organs. The VHL gene has been localized to chromosome 3p25-26 and >500 germline mutations have been identified. A rare variant of the VHL gene results in the substitution of lysine for proline at position 25 (P25L) in the larger of the two VHL proteins. This VHL variant has previously been described in a limited number of cases and has been strongly suggested to be non-pathogenic, but this has not been proven. METHODS: A family with a medical history suggestive of VHL disease was investigated using DNA sequence analysis to determine the presence of the P25L variant of the VHL protein. RESULTS: Sequence analysis identified the VHL P25L variant in 7 of 14 family members, one of whom had a single retinal hemangioma, which is in itself insufficient to diagnose VHL disease. The variant was not identified in a family member with clear cell renal carcinoma, which is a hallmark feature of VHL disease. CONCLUSIONS: On the basis of these results, it is concluded that P25L is a benign variant of the VHL protein and individuals carrying this variant should not be required to undergo screening for VHL manifestations.